| Literature DB >> 33083489 |
Abstract
Curcumin exhibits antibacterial, antioxidant, and anti-inflammatory effects and has been suggested as a treatment for inflammatory diseases. The study is aimed at evaluating the effect of curcumin gel on serum levels of micronutrients (zinc, copper, and magnesium) and proinflammatory cytokines (IL-1β and TNF-α) in chronic periodontitis patients. Ninety subjects with an age of 25-54 were included in this study. From the total number, 30 subjects with healthy periodontium (control group) (mean age = 37.30 ± 7.08) were employed for the sole purpose of obtaining the normal mean values of clinical, chemical, and immunological parameters, and 60 with chronic periodontitis (mean age = 36.73 ± 6.22) were divided randomly into 2 groups, of which each group included 30 subjects. Group A received scaling and root planing SRP and curcumin gel injection covered by Coe pack for 7 days, and group B received SRP alone covered by Coe pack. Clinical parameters (plaque index, gingival index, bleeding on probing, pocket depth, and clinical attachment loss measurements) and blood samples were collected before and after 1 month of treatment to measure serum levels of zinc, copper, magnesium, IL-1β, and TNF-α. The results showed significant micronutrient alteration and increase of proinflammatory cytokines in the chronic periodontitis group as compared to healthy control (P ≤ 0.05), and curcumin gel had a significant effect on the reduction of IL-1β, TNF-α, copper, and clinical parameters (P ≤ 0.05) and increase of zinc and magnesium levels after 1 month as compared to baseline (P ≤ 0.05), nearly the same pattern for group B but with nonsignificant differences for Zn (P > 0.05). In conclusion, curcumin gel resulted in a more significant reduction in clinical parameters, inflammatory mediators, and copper and increase of zinc and magnesium levels as compared to SRP alone.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33083489 PMCID: PMC7559506 DOI: 10.1155/2020/8850926
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Age and gender distribution of study groups.
| Variables | Levels | Healthy control | Periodontitis groups | All groups | |||
|---|---|---|---|---|---|---|---|
| No | % | No | % | No | % | ||
| Age | 25-34 | 8 | 26.7% | 11 | 18.3% | 19 | 21.1% |
| 35-44 | 19 | 63.3% | 42 | 70.0% | 61 | 67.8% | |
| 45-54 | 3 | 10.0% | 7 | 11.7% | 10 | 11.1% | |
| Total | 30 | 100% | 60 | 100% | 90 | 100% | |
| Mean ± SD | 37.30 ± 7.08 | 36.73 ± 6.22 | 37.06 ± 6.50 | ||||
| Gender | Male | 13 | 43.3% | 22 | 36.7% | 35 | 38.9% |
| Female | 17 | 56.7% | 38 | 63.3% | 55 | 61.1% | |
| Total | 30 | 100% | 60 | 100% | 90 | 100% | |
Intragroup comparison of mean ± Std. Deviation of clinical parameters before and after 1 month of therapy in groups A and B using paired t-test.
| Group | Index | Time | Mean |
| Std. deviation | t-test | df. |
|
|---|---|---|---|---|---|---|---|---|
| Group A | PI | Before | 2.127 | 30 | 0.177 | 36.546 | 29 |
|
| After | 0.533 | 30 | 0.184 | |||||
| GI | Before | 2.103 | 30 | 0.133 | 59.024 | 29 |
| |
| After | 0.618 | 30 | 0.081 | |||||
| BOP | Before | 70.869 | 30 | 4.950 | 65.398 | 29 |
| |
| After | 20.847 | 30 | 3.038 | |||||
| PPD | Before | 4.650 | 30 | 0.544 | 18.259 | 29 |
| |
| After | 3.067 | 30 | 0.173 | |||||
| CAL | Before | 5.250 | 30 | 0.469 | 21.627 | 29 |
| |
| After | 3.583 | 30 | 0.265 | |||||
|
| ||||||||
| Group B | PI | Before | 2.017 | 30 | 0.102 | 40.835 | 29 |
|
| After | 0.693 | 30 | 0.141 | |||||
| GI | Before | 2.047 | 30 | 0.183 | 35.066 | 29 |
| |
| After | 0.925 | 30 | 0.104 | |||||
| BOP | Before | 68.161 | 30 | 6.316 | 34.272 | 29 |
| |
| After | 31.547 | 30 | 4.075 | |||||
| PPD | Before | 4.617 | 30 | 0.409 | 22.321 | 29 |
| |
| After | 3.233 | 30 | 0.254 | |||||
| CAL | Before | 5.100 | 30 | 0.635 | 16.37 | 29 |
| |
| After | 4.067 | 30 | 0.254 | |||||
P ≤ 0.05 was considered as significant.
Intragroup comparison of mean ± Std. Deviation of serum Zn, Cu, and Mg levels at baseline before therapy and 1 month after therapy in both A and B groups using paired t-test.
| Group | Index | Time | Mean |
| Std. deviation |
| df |
|
|---|---|---|---|---|---|---|---|---|
| Group A | Mg | Before | 1.540 | 30 | 0.081 | -13.131 | 29 |
|
| After | 1.827 | 30 | 0.087 | |||||
| Zn | Before | 130.532 | 30 | 33.892 | -4.296 | 29 |
| |
| After | 171.273 | 30 | 61.448 | |||||
| Cu | Before | 199.364 | 30 | 32.004 | 7.109 | 29 |
| |
| After | 178.747 | 30 | 31.504 | |||||
|
| ||||||||
| Group B | Mg | Before | 1.540 | 30 | 0.067 | -5.135 | 29 |
|
| After | 1.607 | 30 | 0.058 | |||||
| Zn | Before | 97.667 | 30 | 6.031 | -0.107 | 29 | 0.915 (NS) | |
| After | 97.897 | 30 | 14.952 | |||||
| Cu | Before | 186.577 | 30 | 34.583 | 3.775 | 29 | 0.001 (HS) | |
| After | 159.444 | 30 | 12.792 | |||||
P ≤ 0.05 was considered as significant.
Intragroup comparison of mean ± Std. Deviation of serum proinflammatory cytokine IL-1β and TNF-α levels at baseline before therapy and 1 month after therapy in both A and B groups using paired t-test.
| Group | Index (pg/ml) | Time | Mean |
| Std. deviation |
| df |
|
|---|---|---|---|---|---|---|---|---|
| Group A | IL-1 | Before | 5.036 | 30 | 0.609 | 36.49 | 29 |
|
| After | 3.450 | 30 | 0.486 | |||||
| TNF- | Before | 10.561 | 30 | 0.713 | 25.234 | 29 |
| |
| After | 7.374 | 30 | 0.652 | |||||
|
| ||||||||
| Group B | IL-1 | Before | 10.561 | 30 | 0.606 | 7.114 | 29 |
|
| After | 4.534 | 30 | 0.529 | |||||
| TNF- | Before | 10.519 | 30 | 0.717 | 22.213 | 29 |
| |
| After | 8.483 | 30 | 0.453 | |||||
P ≤ 0.05 was considered as significant.
Intergroup comparison of curcumin (group A) and SRP groups (group B) after 1 month of therapy using unpaired t-test.
| Parameters | Time | Group |
| Mean | Std. deviation |
| df |
|
|---|---|---|---|---|---|---|---|---|
| PI | After therapy | Group A | 30 | 0.533 | 0.184 | -3.772 | 58 |
|
| Group B | 30 | 0.693 | 0.141 | (HS) | ||||
| GI | After therapy | Group A | 30 | 0.618 | 0.081 | -12.746 | 58 |
|
| Group B | 30 | 0.925 | 0.104 | (HS) | ||||
| BOP | After therapy | Group A | 30 | 20.847 | 3.038 | -11.53 | 58 |
|
| Group B | 30 | 31.547 | 4.075 | (HS) | ||||
| PPD | After therapy | Group A | 30 | 3.067 | 0.173 | -2.973 | 58 | 0.004 |
| Group B | 30 | 3.233 | 0.254 | (HS) | ||||
| CAL | After therapy | Group A | 30 | 3.583 | 0.265 | -4.316 | 58 |
|
| Group B | 30 | 4.067 | 0.553 | (HS) | ||||
| Mg | After therapy | Group A | 30 | 1.827 | 0.087 | 11.519 | 58 |
|
| Group B | 30 | 1.607 | 0.058 | (HS) | ||||
| Zn | After therapy | Group A | 30 | 171.273 | 61.448 | 6.355 | 58 |
|
| Group B | 30 | 97.897 | 14.952 | (HS) | ||||
| Cu | After therapy | Group A | 30 | 178.747 | 31.504 | 3.109 | 58 | 0.003 |
| Group B | 30 | 159.444 | 12.792 | (HS) | ||||
| IL-1 | After therapy | Group A | 30 | 3.450 | 0.486 | -8.261 | 58 |
|
| Group B | 30 | 4.534 | 0.529 | (HS) | ||||
| TNF- | After therapy | Group A | 30 | 7.374 | 0.652 | -7.653 | 58 |
|
| Group B | 30 | 8.483 | 0.453 | (HS) |
P ≤ 0.05 was considered as significant.
Intergroup comparison of healthy control with chronic periodontitis A and B groups at baseline before therapy using unpaired t-test.
| Mean ± SD |
| df |
| Sig. | ||
|---|---|---|---|---|---|---|
| Parameters | Control | Group A | ||||
| Group B | ||||||
| PI | 0.100 ± 0.079 | 2.127 ± 0.178 | 57.161 | 58 |
| (HS) |
| 2.017 ± 0.102 | 81.458 | 58 |
| (HS) | ||
| GI | 0.070 ± 0.092 | 2.103 ± 0.133 | 69.13 | 58 |
| (HS) |
| 2.047 ± 0.183 | 52.945 | 58 |
| (HS) | ||
| BOP | 0.000 ± 0.000 | 70.869 ± 4.95 | 78.425 | 58 |
| (HS) |
| 68.161 ± 6.316 | 59.108 | 58 |
| (HS) | ||
| PPD | 1.583 ± 0.708 | 4.650 ± 0.544 | 18.813 | 58 |
| (HS) |
| 4.617 ± 0.409 | 20.322 | 58 |
| (HS) | ||
| CAL | 0.000 ± 0.000 | 5.250 ± 0.469 | 61.331 | 58 |
| (HS) |
| 5.100 ± 0.635 | 43.978 | 58 |
| (HS) | ||
| Zn | 92.260 ± 13.510 | 130.532 ± 33.892 | 5.745 | 58 | 0.050 | (S) |
| 97.667 ± 6.031 | 2.002 | 58 |
| (HS) | ||
| Mg | 1.880 ± 0.092 | 1.540 ± 0.081 | -15.119 | 58 |
| (HS) |
| 1.540 ± 0.067 | -16.268 | 58 |
| (HS) | ||
| Cu | 52.847 ± 8.873 | 199.364 ± 32.004 | 24.164 | 58 |
| (HS) |
| 186.577 ± 34.583 | 20.516 | 58 |
| (HS) | ||
| IL-1 | 3.120 ± 0.352 | 5.036 ± 0.609 | 14.909 | 58 |
| (HS) |
| 4.951 ± 0.606 | 14.304 | 58 |
| (HS) | ||
| TNF- | 7.188 ± 0.803 | 10.561 ± 0.713 | 17.205 | 58 |
| (HS) |
| 10.519 ± 0.717 | 16.944 | 58 |
| (HS) | ||
P ≤ 0.05 was considered as significant.
Intergroup comparison of healthy control with curcumin (A) and SRP groups (B) after 1 month of therapy using unpaired t-test.
| Mean ± SD |
| df |
| Sig. | ||
|---|---|---|---|---|---|---|
| Parameters | Control | Group A | ||||
| Group B | ||||||
| PI | 0.100 ± 0.079 | 0.533 ± 0.184 | 11.833 | 58 |
| (HS) |
| 0.693 ± 0.141 | 20.092 | 58 |
| (HS) | ||
| GI | 0.070 ± 0.092 | 0.618 ± 0.081 | 24.573 | 58 |
| (HS) |
| 0.925 ± 0.104 | 33.779 | 58 |
| (HS) | ||
| BOP | 0.000 ± 0.000 | 20.847 ± 3.038 | 37.585 | 58 |
| (HS) |
| 31.547 ± 4.075 | 42.4 | 58 |
| (HS) | ||
| PPD | 1.583 ± 0.708 | 3.067 ± 0.173 | 11.146 | 58 |
| (HS) |
| 3.233 ± 0.254 | 12.015 | 58 |
| (HS) | ||
| CAL | 0.000 ± 0.000 | 3.583 ± 0.265 | 73.97 | 58 |
| (HS) |
| 4.067 ± 0.553 | 40.283 | 58 |
| (HS) | ||
| Mg | 1.880 ± 0.092 | 1.827 ± 0.087 | -2.303 | 58 |
| (S) |
| 1.607 ± 0.058 | -13.693 | 58 |
| (HS) | ||
| Zn | 92.260 ± 13.510 | 171.273 ± 61.448 | 6.879 | 58 |
| (HS) |
| 97.897 ± 14.952 | 1.532 | 58 | 0.131 | (NS) | ||
| Cu | 52.847 ± 8.873 | 178.747 ± 31.504 | 21.069 | 58 |
| (HS) |
| 3.120 ± 0.352 | 159.444 ± 12.792 | 37.503 | 58 |
| (HS) | |
| IL-1 | 3.45 ± 0.486 | 3.009 | 58 | 0.004 | (HS) | |
| 7.188 ± 0.803 | 4.534 ± 0.529 | 12.184 | 58 |
| (HS) | |
| TNF- | 7.374 ± 0.652 | 0.989 | 58 | 0.327 | (NS) | |
| 8.483 ± 0.453 | 7.695 | 58 |
| (HS) | ||
P ≤ 0.05 was accepted as statistically significant.